Elanco Animal Health (NYSE:ELAN) Issues Quarterly Earnings Results

Elanco Animal Health (NYSE:ELAN) issued its earnings results on Tuesday. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01), Zacks reports. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company posted $0.08 earnings per share.

Elanco Animal Health Stock Performance

ELAN opened at $10.71 on Wednesday. The business has a 50 day moving average price of $11.75 and a two-hundred day moving average price of $13.07. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market capitalization of $5.29 billion, a price-to-earnings ratio of 26.76, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 1-year low of $10.20 and a 1-year high of $18.80.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ELAN shares. UBS Group assumed coverage on Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. Morgan Stanley lowered their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.86.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.